Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features

Leukemia and Lymphoma

Volumn 46, Issue 5, 2005, Pages 663-670

  Eisendle, Klaus ^a   Wolf, Dominik ^a   Gastl, Guenther ^a   Kircher Eibl, Brigitte ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CML; Dendritic cell; Imatinib mesylate; Immunotherapy; T cell; Tumor necrosis factor ; Vaccination

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BCR ABL PROTEIN; CELL ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; IMATINIB; KEYHOLE LIMPET HEMOCYANIN; PLANT EXTRACT; QUILLAJA SAPONARIA EXTRACT; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CELL STRUCTURE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG MECHANISM; DRUG SAFETY; ENDOCYTOSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; IN VITRO STUDY; PHAGOCYTOSIS; PHENOTYPE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QUILLAJA; QUILLAJA SAPONARIA; REVIEW; TUMOR IMMUNITY; VACCINATION; VOLUNTEER;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOCYTE ACTIVATION; MYELOID CELLS; PIPERAZINES; PYRIMIDINES; T-LYMPHOCYTES;

EID: 20144373476     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400029825     Document Type: Review

References (67)

1. Lee SJ. Chronic myelogenous leukaemia. Br J Haematol 2000;111:993-1009.
2. Mughal TI, Goldman JM. Chronic myeloid leukemia: current status and controversies. Oncology 2004;18:837-844.
3. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2003;11:35-43.
4. Kaminski ER, Goddard RV, Prentice AG. Dendritic cells and their potential therapeutic role in haematological malignancy. Leuk Lymphoma 2003;44:1657-1666.
5. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-1186.
6. +/CD38-primitive haematopoietic progenitors. Br J Haematol 2002; 119:115-118.
7. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, Degos L, Dombret H, Toubert A, Rea D. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004;18:1656-1661.
8. Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D, Isnardon D, Olive D, Gaugler B. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004;103:4666-4668.
9. Eibl B, Ebner S, Duba C, Bock G, Romani N, Erdel M, Gachter A, Niederwieser D, Schuler G. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997;20:215-223.
10. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-1142.
11. Dietz AB, Bulur PA, Erickson MR, Wettstein PJ, Litzow MR, Wyatt WA, Dewald GW, Tefferi A, Pankratz VS, Vuk-Pavlovic S. Optimizing preparation of normal dendritic cells and bcr-abl + mature dendritic cells derived from immunomagnetically purified CD14 + cells. J Hematother Stem Cell Res 2000;9:95-101.
12. Zheng C, Pisa P, Stromberg O, Blennow E, Hansson M. Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia. Med Oncol 2000;17:270-278.
13. Eisendle K, Lang A, Eibl B, Nachbaur D, Glassl H, Fiegl M, Thaler J, Gastl G. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 2003;120:63-73.
14. Westermann J, Körner IJ, Kopp J, Kurz S, Zenke M, Dorken B, Pezzutto A. Cyropreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 2003;52:194-198.
15. Smit WM, Rijnbeek M, van Bergen CA, de Paus RA, Vervenne HA, van de Keur M, Willemze R, Falkenburg JH. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol 1997;53:216-223.
16. Wang C, Al-Omar HM, Radvanyi L, Banerjee A, Bouman D, Squire J, Messner HA. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha. Exp Hematol 1999;27:1176-1184.
17. Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foa R, Belardelli F. IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004;103:980-987.
18. Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 2002;16:1484-1489.
19. Engels FHC, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci USA 1999;96:10332-10337.
20. Kharfan-Dabaja MA, Ayala E, Lindner I, Cejas PJ, Bahlis NJ, Kolonias D, Carlson LM, Lee KP. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother 2005;54:25-36.
21. Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol 2003;171:1780-1791.
22. Wang L, Butt NM, Atherton MG, Clark RE. Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. Leukemia 2004;18:1025-1027.
23. Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, Goldman JM, Melo JV, Lechler RI, Bellantuono I, Ridley A, Lombardi G. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003;101:3560-3567.
24. Heinzinger M, Waller CF, von den BA, Rosenstiel A, Lange W. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol 1999;78:181-186.
25. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103.
26. Lyakh LA, Koski GK, Telford W, Gress RE, Cohen PA, Rice NR. Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. J Immunol 2000;165:3647-3655.
27. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781-1787.
28. Müller L, Provenzani C, Faul C, Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br J Haematol 2001;112:740-748.
29. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258.
30. Figdor CG, de Vries JM, Lesterhuis JW, Melief CJM. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480.
31. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
32. Al-Alwan MM, Liwski RS, Haeryfar SM, Baldridge WH, Hoskin DW, Rowden G, West KA. Cutting edge: dendritic cell actin cytoskeletal polarization during immunological synapse formation is highly antigen-dependent. J Immunol 2003;171:4479-4483.
33. Zhou LJ, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 1995;86:3295-3301.
34. Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Ait-Yahia S, Banchereau J, Liu YJ, Lebecque S, Caux C. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998;160:1666-1676.
35. Huang YM, Xiao BG, Westerlund I, Link H. Phenotypic and functional properties of dendritic cells isolated from human peripheral blood in comparison with mononuclear cells and T cells. Scand J Immunol 1999;49:177-183.
36. Pashenkov M, Kouwenhoven MC, Ozenci V, Huang YM. Phenotypes and cytokine profiles of enriched blood dendritic cells in healthy individuals. Eur Cytokine Netw 2000;11:456-463.
37. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
38. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
39. Ibelgaufts H. Dictionary of cytokines. Wiley-VCH, New York Editiones Roche; 1995. p 709-717.
40. Strieter RM, Koch AE, Antony VB, Fick RB Jr, Standiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994;123:183-197.
41. Bertalozzi C, Marchesi E, Passoni L, Barni R, Ravagnani F, Lombardo C, Corneo GM, Pioltelli P, Pogliani E, Gambacorti-Passerini C. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res 2000;6:1931-1935.
42. Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A, Foa R. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemic patients in complete haematological remission. Br J Haematol 2001;113:136-142.
43. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian MH, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res 2000;6:1671-1677
44. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
45. Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, Tadokoro K, Juji T. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998;91:977-983.
46. Narita M, Takahashi M, Liu A, Nikkuni K, Furukawa T, Toba K, Koyama S, Takai K, Sanada M, Aizawa Y. Leukemia blast-induced T-cell anergy demonstrated by leukaemia-derived dendritic cells in acute myelogenous leukaemia. Exp Hematol 2001;29:709-719.
47. Mannering SI, McKenzie JL, Hart DN. Optimisation of the conditions for generating human DC initiated antigen specific T lymphocyte lines in vitro. J Immunol Meth 1998;219:69-83.
48. Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, Furukawa T, Aoki S, Aizawa Y. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999;13:166-174.
49. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290-2296.
50. Clark RE, Dodi AI, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001;98:2887-2893.
51. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423.
52. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
53. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
54. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104.
55. Cools JJ, DeAngelo DJ, Gotlib J, Stover EH, Legate RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
56. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
57. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
58. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
59. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brummendorf TH, Brossart P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103:538-544.
60. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995;373:531-536.
61. Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 2004;103:1966-1967.
62. Sato N, Narita M, Takahashi M, Yagisawa K, Liu A, Abe T, Nikkuni K, Furukawa T, Toba K, Aizawa Y. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003;21:67-75.
63. Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005;105:1135-1143.
64. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037-1042.
65. Lim SH, Coleman S, Bailey-Wood R. In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia. Bone Marrow Transplant 1998;22:1185-1190.
66. Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leukemia Res 2003;27:795-802.
67. Ossenkoppele GJ, Stam AM, Westers TM, de Gruijl TD, Janssen JJ, van de Loosdrecht AA, Scheper RJ. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003;17:1424-1426.